{"id":125216,"date":"2021-07-29T08:00:00","date_gmt":"2021-07-29T08:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2896271"},"modified":"2021-07-29T08:00:00","modified_gmt":"2021-07-29T08:00:00","slug":"pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/","title":{"rendered":"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Pulmonary-Arterial-Hypertension-PAH-Market.jpg?1627533045321\" alt=\"Pulmonary-Arterial-Hypertension-PAH-Market\" width=\"650\" height=\"216\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight\u2019s <\/span><strong>Pulmonary Arterial Hypertension (PAH) Market Insights Report<\/strong><span style=\"font-weight: 400;\"> offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into Pulmonary Arterial Hypertension (PAH) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing the growth of market size forward.\u00a0<\/span><\/p>\n<p><strong>Some of the key highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Market<\/strong><\/a><strong> Insights:\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pulmonary Arterial Hypertension is a rare disorder that affects around 15 to 50 persons per million in the United States and Europe.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">As per the DelveInsight estimates, among the 7MM, the United States accounted for the highest <\/span><strong>Pulmonary Arterial Hypertension prevalent population<\/strong><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">PAH is classified based on underlying disease mechanisms. Among different <\/span><strong>subtypes of Pulmonary Arterial Hypertension<\/strong><span style=\"font-weight: 400;\">, Idiopathic PAH contributes the major patient share of PAH followed by CTD-PAH and Drug\/Toxin Induced PAH. On the other hand, Heritable PAH and HIV-related PAH contribute the lowest patient share of PAH.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Among the 7MM, the females have a high prevalence of Pulmonary Arterial Hypertension as compared to males. Women between the ages of 30 and 60 years are found to be more affected by Pulmonary Arterial Hypertension as compared to other age groups.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">To provide effective therapeutics options, currently, some of the key companies such as <\/span><strong>United Therapeutics, Arena Pharmaceuticals, Altavant Sciences, Acceleron Pharma, Reata Pharmaceuticals, Complexa, Liquidia Technologies, PhaseBio Pharmaceuticals, <\/strong><span style=\"font-weight: 400;\">and several others are diligently involved in developing Pulmonary Arterial Hypertension Therapies.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Presently, the <\/span><strong>Pulmonary Arterial Hypertension Therapeutics Market<\/strong><span style=\"font-weight: 400;\"> is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors. Several of the therapies are in the various developmental stages which is expected to launch in the near future.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">In the coming years, key factors such as an increase in the prevalence of Pulmonary Arterial Hypertension, approval of the pipeline therapies, and the extensive research and development activities of the pharma companies are expected to drive the <\/span><strong>Pulmonary Arterial Hypertension Market<\/strong><span style=\"font-weight: 400;\">.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Some of the key <\/span><strong>therapies in the Pulmonary Arterial Hypertension Market<\/strong><span style=\"font-weight: 400;\"> include Aurora-GT, Ralinepag, RVT-1201, Sotatercept, Bardoxolone methyl, Inhaled dry powder treprostinil, PB1046 Injection, CXA-10, and others.\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Learn more by requesting for sample @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Market Landscape<\/strong><span style=\"font-weight: 400;\">\u00a0<\/span><\/a><\/p>\n<p><strong>Pulmonary Arterial Hypertension: Overview<br \/>\n<\/strong><span style=\"font-weight: 400;\">Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and life-threatening condition. It is a progressive form of Pulmonary Hypertension that results in high blood pressure in the lungs. The disease progress with time and gets worse if remains untreated. Among various subtypes, the Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all Pulmonary Arterial Hypertension cases.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The exact cause of PAH is unknown. Some of the factors such as age, gender, genetics, environment, family history, and lifestyle habits increase the risk for Pulmonary Arterial Hypertension. At present, some of the treatments options such as supportive therapy, pharmacological treatment, and Surgical Treatment are available in the <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension (PAH) Market<\/strong><\/a><span style=\"font-weight: 400;\"> that to improve the symptoms and slowing the rate of clinical deterioration.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For more insights into Disease, causes, and treatment, reach out @\u00a0<\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Treatment Landscape<\/strong><\/a><strong>\u00a0<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Epidemiology Segmentation<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><strong>Pulmonary Arterial Hypertension Market<\/strong><span style=\"font-weight: 400;\"> report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Total prevalent patient population of Pulmonary Arterial Hypertension<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Gender-specific prevalence Pulmonary Arterial Hypertension<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Sub-type specific prevalence of Pulmonary Arterial Hypertension<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Visit for more @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Epidemiological Insights<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">At present, the approved therapies in the Pulmonary Arterial Hypertension Market aim to promote dilation of the pulmonary vessels to reduce pulmonary vascular resistance. These therapies are administered alone or in combination to improve and slow the progression of the disease. The therapeutics market lack treatment option that can directly address the underlying cellular proliferation which causes increased pulmonary arterial pressure.<br \/>\n<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In the coming years, the increase in the aging population, R&amp;D activities of pharmaceutical companies, improvement in diagnostic imaging technologies, and the approval of the pipeline therapies are expected to drive the <\/span><strong>Pulmonary Arterial Hypertension Market Growth<\/strong><span style=\"font-weight: 400;\"> in a positive direction.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Pipeline Therapies and Key Companies<\/strong><span style=\"font-weight: 400;\">\u00a0<\/span><\/a><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Aurora-GT &#8211; <\/strong><span style=\"font-weight: 400;\">United Therapeutics<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Ralinepag &#8211; <\/strong><span style=\"font-weight: 400;\">Arena Pharmaceuticals<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>RVT-1201 &#8211; <\/strong><span style=\"font-weight: 400;\">Altavant Sciences\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Sotatercept <\/strong><span style=\"font-weight: 400;\">&#8211; Acceleron Pharma<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>CXA-10<\/strong><span style=\"font-weight: 400;\"> &#8211; Complexa<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Bardoxolone methyl<\/strong><span style=\"font-weight: 400;\"> &#8211; Reata Pharmaceuticals\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Inhaled dry powder treprostinil <\/strong><span style=\"font-weight: 400;\">&#8211; Liquidia Technologies<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>PB1046 Injection<\/strong> &#8211; PhaseBio Pharmaceuticals<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">For more information, visit <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Market Analysis, Patient Pool, and Emerging Therapies<\/strong><\/a><\/p>\n<p><strong>Pulmonary Arterial Hypertension Market Drivers<\/strong><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Approval of the pipeline therapies<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Increase in the prevalence of Pulmonary Arterial Hypertension<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Extensive research and development activities<\/span><\/li>\n<\/ul>\n<p><strong>Scope of the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">11 Years Forecast<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">7MM Coverage\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Descriptive overview of Pulmonary Arterial Hypertension, covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Comprehensive insight into Pulmonary Arterial Hypertension epidemiology and treatment in the 7MM<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Current and emerging therapies for Pulmonary Arterial Hypertension<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pulmonary Arterial Hypertension market drivers and barriers\u00a0<\/span><\/li>\n<\/ul>\n<p><strong>Key Questions Answered in the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What was the <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension market share<\/strong><\/a><span style=\"font-weight: 400;\"> (%) distribution in 2017 and how it would look like in 2030?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What would be the Pulmonary Arterial Hypertension total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the key findings pertaining to the market across 7MM and which country will have the largest Pulmonary Arterial Hypertension market size during the forecast period (2017-2030)?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">At what CAGR, the Pulmonary Arterial Hypertension market is expected to grow in 7MM during the forecast period (2017-2030)?<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Get in touch with our Business executive @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Market Landscape Analysis<\/strong><\/a><\/p>\n<p><strong>Table of Contents\u00a0<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>1<\/strong><\/td>\n<td><strong>Key Insights<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>2<\/strong><\/td>\n<td><strong>Report Introduction<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>3<\/strong><\/td>\n<td><strong>Competitive Intelligence Analysis for Pulmonary Arterial Hypertension (PAH)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>4<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>5<\/strong><\/td>\n<td><strong>Executive Summary of Pulmonary Arterial Hypertension (PAH)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>6<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Epidemiology and Market Methodology<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>7<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Epidemiology and Patient Population<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>8<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Patient Journey<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>9<\/strong><\/td>\n<td><strong>Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>10<\/strong><\/td>\n<td><strong>Key Endpoints in Pulmonary Arterial Hypertension (PAH) Clinical Trials<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>11<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Marketed Therapies\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>12<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Emerging Therapies<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>13<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>14<\/strong><\/td>\n<td><strong>Attribute analysis<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>15<\/strong><\/td>\n<td><strong>Access and Reimbursement Overview of Pulmonary Arterial Hypertension (PAH)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>16<\/strong><\/td>\n<td><strong>KOL Reviews<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>17<\/strong><\/td>\n<td><strong>Case Reports<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>18<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Market Drivers<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>19<\/strong><\/td>\n<td><strong>Pulmonary Arterial Hypertension (PAH) Market Barriers<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>20<\/strong><\/td>\n<td><strong>SWOT Analysis<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>21<\/strong><\/td>\n<td><strong>Disclaimer<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>22<\/strong><\/td>\n<td><strong>DelveInsight Capabilities<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>23<\/strong><\/td>\n<td><strong>About DelveInsight<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Learn more about the report offerings @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/pulmonary-arterial-hypertension-pah-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Market Outlook<\/strong><\/a><\/p>\n<p><strong>Related Reports<\/strong><span style=\"font-weight: 400;\"> &#8211;<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-epidemiology-forecast?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Epidemiology Forecast<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight&#8217;s Pulmonary Arterial Hypertension &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of the disease in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Pulmonary Arterial Hypertension Pipeline Insights<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">Pulmonary Arterial Hypertension Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Pulmonary Arterial Hypertension Market.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\"><strong>mRNA Vaccines and Therapeutics Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u2018Global Messenger RNA (mRNA) based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast 2030\u2019 report deliver an in-depth understanding of the mRNA-based Vaccines and Therapeutics, along with its historical and forecasted epidemiology and market trends in North America, Europe, Asia, and ROW (rest of the world).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market\"><strong>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/bevacizumab-biosimilars-insight\"><strong>Bevacizumab Biosimilars Insight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s, \u201cBevacizumab Biosimilar Insight, 2020,\u201d report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/corneal-endothelial-dystrophy-market\"><strong>Corneal Endothelial Dystrophy Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/lennox-gastaut-syndrome-market\"><strong>Lennox Gastaut Syndrome Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight&#8217; s \u201cLennox Gastaut Syndrome Market Insights, Epidemiology and Market Forecast &#8211; 2030\u201d report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Lennox Gastaut Syndrome market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Healthcare Blogs<\/strong><\/a><strong> &#8211;\u00a0<\/strong><\/p>\n<ul>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">JAK inhibitors Pipeline<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/diabetic-macular-edema-therapy-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Diabetic Macular Edema Market Developments<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/implantable-cardiac-monitors-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Implantable Cardiac Monitors Market Growth<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/neurovascular-thrombectomy-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Neurovascular Thrombectomy Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/vagus-nerve-stimulator-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Vagus Nerve Stimulator Market Share<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/pros-and-cons-of-wearable-devices\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Wearable Technology Advantages and Disadvantages<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/age-related-hearing-loss-device-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Age-Related Hearing Loss Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/femtech-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Companies in FemTech Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/technology-and-autism-spectrum-disorder\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Impact of Technology on People with Autism<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/eye-disorders-treatment-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Common Eye Diseases and Treatments<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/insulin-delivery-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Key Companies in Insulin Delivery Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/medical-device-2021\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Leading Medtech Companies<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/presbyopia-treatment-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Key Companies in the Presbyopia Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/spinal-stenosis-devices-market-size\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Spinal Stenosis Devices Market Share<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/bone-cancer-treatment-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Bone Cancer Therapeutics Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/cardiac-monitoring-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Cardiac Monitoring Devices Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/skin-cancer-treatment-market-and-key-companies\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Pharma Companies in Skin Cancer Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/transcranial-stimulation-devices-market\/\">Transcranial Stimulation Devices Market Growth<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/uncomplicated-urinary-tract-infections-market\/\">Key Companies in the Uncomplicated Urinary Tract Infections Market<\/a><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-autoimmune-diseases-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Companies in Autoimmune Diseases Treatment Market<\/a>\u00a0<\/strong><\/li>\n<\/ul>\n<p><strong>Get in touch with our Business executive for<\/strong><a href=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"> <strong>Competitive Intelligence Services<\/strong><\/a><\/p>\n<p><strong>About<\/strong><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"> <strong>DelveInsight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform<\/span><a href=\"https:\/\/www.pharmdelve.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"> <strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Connect With Us at<\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"> <strong>LinkedIn<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"><strong> Facebook<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"><strong> Twitter<\/strong><\/a><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/pulmonary-arterial-hypertension-market\/\" rel=\"tag\">Pulmonary Arterial Hypertension Market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/pulmonary-arterial-hypertension\/\" rel=\"tag\">Pulmonary Arterial Hypertension<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/hypertension\/\" rel=\"tag\">Hypertension<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/pulmonary-arterial-hypertension-pipeline\/\" rel=\"tag\">Pulmonary Arterial Hypertension Pipeline<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/pulmonary-arterial-hypertension-epidemiology\/\" rel=\"tag\">Pulmonary Arterial Hypertension Epidemiology<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Shruti Thakur\u00a0 info@delveinsight.com\u00a0 +91-9650213330<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/pr-wirein\/\" rel=\"category tag\">PR-Wirein<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Shruti Thakur\u00a0 info@delveinsight.com\u00a0 +91-9650213330<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\">Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s Pulmonary Arterial Hypertension (PAH) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into Pulmonary Arterial Hypertension (PAH) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\">Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-125216","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&rsquo;s Pulmonary Arterial Hypertension (PAH) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into Pulmonary Arterial Hypertension (PAH) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively [&hellip;] The post Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T08:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\",\"name\":\"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"datePublished\":\"2021-07-29T08:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/","og_locale":"en_US","og_type":"article","og_title":"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics - Business","og_description":"DelveInsight&rsquo;s Pulmonary Arterial Hypertension (PAH) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into Pulmonary Arterial Hypertension (PAH) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively [&hellip;] The post Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/","og_site_name":"Business","article_published_time":"2021-07-29T08:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/","url":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/","name":"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","datePublished":"2021-07-29T08:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/07\/29\/pulmonary-arterial-hypertension-pah-market-to-grow-substantially-owing-to-the-initiatives-by-key-companies-in-the-therapeutics-domain-such-as-arena-pharma-altavant-sciences-acceleron-reata-compl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Pulmonary Arterial Hypertension (PAH) Market to Grow Substantially Owing to the Initiatives by Key Companies in the Therapeutics Domain such as Arena Pharma, Altavant Sciences, Acceleron, Reata, Complexa, Liquidia Technologies, and United Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/125216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=125216"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/125216\/revisions"}],"predecessor-version":[{"id":125217,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/125216\/revisions\/125217"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=125216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=125216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=125216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}